Immunic's vidofludimus calcium reduces disability worsening risk by 30% in PPMS from phase 2 CALLIPER trial

IMMUNIC, INC.

Vidofludimus calcium reduced 24-week confirmed disability worsening risk by 20% overall (n=467) vs placebo.
In PPMS subgroup (n=152), risk reduced by 30%; in non-active SPMS (n=268) by 15%.
Reduced annualized thalamic brain volume loss by 20% vs placebo; T2 lesion burden improved.
Safety profile consistent with prior trials: TEAEs 69.4% (drug) vs 68.5% (placebo); SAEs 8.1% vs 6.5%.
Company plans to discuss phase 3 registration path with healthcare authorities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.